Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects With Moderate-to-Severe Atopic Dermatitis

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects With Moderate-to-Severe Atopic Dermatitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2018

At a glance

  • Drugs Etokimab (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Acronyms ATLAS
  • Sponsors AnaptysBio
  • Most Recent Events

    • 07 Aug 2018 According to an AnaptysBio media release, data from this study is expected in second half of 2019.
    • 08 May 2018 Status changed from planning to recruiting, as reported in an AnaptysBio media release.
    • 11 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top